A Phase 3 interventional study of Amivantamab and Osimertinib in Carcinoma, Non-Small-Cell Lung, sponsored by Janssen Research & Development, LLC. Active, not recruiting at 269 sites in 28 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies testing amivantamab in Carcinoma, Non-Small-Cell Lung — 4 open to participants now, 14 under way, 3 of them phase 3. amivantamab · Carcinoma, Non-Small-Cell Lung.
Among the 15 studies testing amivantamab in Carcinoma, Non-Small-Cell Lung, this one has the largest enrollment, is the only one that started in 2020, is one of 3 in phase 3, reaches primary completion later than 1 of the 13 other live ones, and was the 3rd registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →4 of the 15 studies testing amivantamab in Carcinoma, Non-Small-Cell Lung are open now, in 5 countries. Recruiting first, the newest first:
Fondazione Ricerca Traslazionale · Sites in Italy
Ages 18–99
SWOG Cancer Research Network · Sites in United States
Ages 18+
University Hospital, Essen · Sites in Belgium, Germany, Netherlands
Ages 18+
Yonsei University
Ages 19+
By country, each count listing its studies:
amivantamab: first FDA approval 2021 (RYBREVANT), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →
Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 10 · Phase 3 3
First in 2016; this study’s year is marked. 1 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,074 is above the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 80 across the 15 interventional studies. Of the 1 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 15 have an industry lead sponsor. The 8 most frequent:
This study is registered under Janssen Research & Development, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
36 studies in Carcinoma, Non-Small-Cell Lung by Johnson & Johnson: 7 open now, 18 under way, 4 of them phase 3. Of 15 finished, 7 (47%) have results posted.
Among the 36 studies in Carcinoma, Non-Small-Cell Lung by Johnson & Johnson, this one has the largest enrollment of the 28 interventional ones that give a count, is one of 3 that started in 2020, is one of 4 in phase 3, reaches primary completion later than 2 of the 17 other live ones, and was the 17th registered.
Johnson & Johnson’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 2012.
7 of the studies testing amivantamab in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02609776Janssen Research & Development, LLCStudy of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer | 2026-12-31 |
| NCT04077463Janssen Research & Development, LLCA Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer | 2027-02-12 |
| NCT05488314Janssen Research & Development, LLCA Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer | 2027-04-28 |
| NCT06120140Janssen Research & Development, LLCEnhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib | 2027-05-31 |
| NCT06784791University Hospital, EssenPreoperative Amivantamab or Amivantamab and Carboplatin/Pemetrexed Treatment in Patients With Resectable Non-small-cell Lung Cancer Harboring Oncogenic EGFR Mutations (NEOpredict-EGFR) | 2027-07-31 |
Add all 7 to your calendar (.ics) → With an account.
Among the 15 studies testing amivantamab in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Among Johnson & Johnson’s 36 in Carcinoma, Non-Small-Cell Lung:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the efficacy of the amivantamab and lazertinib combination, compared with osimertinib, in participants with epidermal growth factor receptor (EGFR) mutation (Exon 19 deletions [Exon 19del] or Exon 21 L858R substitution) positive, locally advanced or metastatic non-small cell lung cancer (NSCLC).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive amivantamab 1050 milligram (mg) intravenously (IV) for body weight less than (\<) 80 kilogram (kg) and 1400 mg for body weight greater than or equal to (\>=) 80 kg in 28-day cycles: once weekly in Cycle 1 (with a split dose on Days 1-2), and then every 2 weeks in subsequent cycles. Lazertinib will be administered 240 mg (80\*3) orally once daily.
Drug: Amivantamab · Drug: Lazertinib
Participants will receive osimertinib 80 mg orally once daily plus matching placebo of lazertinib 240 mg (80\*3) orally once daily.
Drug: Osimertinib · Drug: Placebo
Participants will receive lazertinib 240 mg (80\*3) orally once daily plus matching placebo of osimertinib 80 mg orally once daily.
Drug: Lazertinib · Drug: Placebo
Participants will receive amivantamab intravenously.
Also known as: JNJ-61186372
Participants will receive osimertinib capsules orally.
Participants will receive lazertinib tablets orally.
Also known as: JNJ-73841937 and YH-25448
Participants will receive matching placebo orally.
Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR)
PFS was defined as the time from randomization until the date of objective disease progression based on BICR using RECIST version 1.1 or death (by any cause) the absence of progression, whichever came first. Disease progression was defined using RECIST 1.1 as a 20 percent (%) increase in the sum of diameters of target measurable lesions above the smallest sum observed, with a minimum absolute increase of 5 millimeters (mL). Participants who have not progressed or have not died at the time of analysis were censored at the time of the latest date of their last evaluable RECIST version 1.1 assessment.
Time frame: From randomization to either disease progression or death whichever occurs first (up to 32.8 months)
Overall Survival (OS)
Overall Survival is defined as the time from the date of randomization to the date of participant's death due to any cause.
Time frame: Approximately 60 months (time from the date of randomization until the date of death due to any cause)
Objective Response Rate (ORR)
ORR is defined as the percentage of participants who achieve either a complete response (CR) or partial response (PR) as defined by BICR using RECIST v1.1 criteria.
Time frame: Approximately 32.8 months
Duration of Response (DOR)
DOR is defined as the time from the date of first documented response (CR or PR) until the date of documented progression or death, whichever comes first, only for participants who achieve CR or PR as determined by the investigator using RECIST v1.1 criteria.
Time frame: Approximately 32.8 months
Progression-Free Survival After First Subsequent Therapy (PFS2)
The PFS2 is defined as the time from randomization until the date of second objective disease progression, after initiation of subsequent anticancer therapy, based on investigator assessment (after that used for PFS) or death, whichever comes first.
Time frame: Approximately 60 months
Time to Symptomatic Progression (TTSP)
TTSP is defined as the time from randomization to documentation in the electronic case report form (eCRF) of any of the following (whichever occurs earlier): onset of new symptoms or symptom worsening that is considered by the investigator to be related to lung cancer and requires either a change in anticancer treatment and/or clinical intervention to manage symptoms.
Time frame: Approximately 60 months
Intracranial PFS
Intracranial PFS is defined as the time from randomization until the date of objective intracranial disease progression or death, whichever comes first, based on BICR using RECIST v1.1.
Time frame: Approximately 60 months
Incidence and Severity of Adverse Events (AEs)
Incidence and severity of treatment emergent adverse events (TEAEs) will be reported. Any adverse event occurring at or after the initial administration of study treatment through the day of last dose plus 30 days, or until the start of subsequent anticancer therapy (if earlier), is considered to be treatment emergent.
Time frame: Approximately 60 months
Number of Participants With Clinical Laboratory Abnormalities
Number of participants with clinical laboratory abnormalities (serum chemistry, hematology, blood coagulation, and urine samples) will be reported.
Time frame: Approximately 60 months
Number of Participants With Vital Signs Abnormalities
Number of participants with vital signs abnormalities (temperature, heart rate, respiratory rate, oxygen saturation, blood pressure) will be reported.
Time frame: Approximately 60 months
Number of Participants With Physical Examination Abnormalities
Number of participants with physical examination abnormalities will be reported.
Time frame: Approximately 60 months
Serum Concentration of Amivantamab
Serum samples will be analyzed to determine concentrations of Amivantamab.
Time frame: Approximately 60 months
Plasma Concentration of Lazertinib
Plasma samples will be analyzed to determine concentrations of Lazertinib.
Time frame: Approximately 60 months
Number of Participants With Anti-Amivantamab Antibodies
Number of participants with antibodies to amivantamab will be reported.
Time frame: Approximately 60 months
Change From Baseline in Non-Small Cell Lung Cancer - Symptom Assessment Questionnaire (NCSLC-SAQ)
The NSCLC-SAQ contains 7 items that assess cough, pain, dyspnea, fatigue, and poor appetite over a 7-day recall period. Each multi-item scale and individual item will be summarized using count and percent by visit.
Time frame: Baseline up to approximately 60 months
Change From Baseline in European Organization of Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC-QLQ-C30)
EORTC-QLQ-C30 is a core 30-item questionnaire for evaluating the health-related quality of life (HRQoL) of participants participating in cancer clinical studies.
Time frame: Baseline up to approximately 60 months
| Milestone | Experimental: Arm A (Open-label): Amivantamab + Lazertinib | Active Comparator: Arm B (Double-blind): Osimertinib+Placebo Matching Lazertinib | Experimental: Arm C (Double-blind): Lazertinib+Placebo Matching Osimertinib |
|---|---|---|---|
| Started | 429 | 429 | 216 |
| Treated | 421 | 428 | 213 |
| Completed | 94 | 113 | 54 |
| Not completed | 335 | 316 | 162 |
| Withdrew: Withdrawal by subject | 19 | 18 | 13 |
| Withdrew: Lost to follow-up | 3 | 1 | 0 |
| Withdrew: Ongoing | 313 | 297 | 149 |
PFS was defined as the time from randomization until the date of objective disease progression based on BICR using RECIST version 1.1 or death (by any cause) the absence of progression, whichever came first. Disease progression was defined using RECIST 1.1 as a 20 percent (%) increase in the sum of diameters of target measurable lesions above the smallest sum observed, with a minimum absolute increase of 5 millimeters (mL). Participants who have not progressed or have not died at the time of analysis were censored at the time of the latest date of their last evaluable RECIST version 1.1 assessment.
| Months | Experimental: Arm A (Open-label): Amivantamab + Lazertinib | Active Comparator: Arm B (Double-blind): Osimertinib+Placebo Matching Lazertinib | Experimental: Arm C (Double-blind): Lazertinib+Placebo Matching Osimertinib |
|---|---|---|---|
| Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) | 23.72 (19.12 to 27.66) | 16.59 (14.78 to 18.46) | 18.46 (14.75 to 20.11) |
Overall Survival is defined as the time from the date of randomization to the date of participant's death due to any cause.
Results for this outcome have not been posted.
ORR is defined as the percentage of participants who achieve either a complete response (CR) or partial response (PR) as defined by BICR using RECIST v1.1 criteria.
Results for this outcome have not been posted.
DOR is defined as the time from the date of first documented response (CR or PR) until the date of documented progression or death, whichever comes first, only for participants who achieve CR or PR as determined by the investigator using RECIST v1.1 criteria.
Results for this outcome have not been posted.
The PFS2 is defined as the time from randomization until the date of second objective disease progression, after initiation of subsequent anticancer therapy, based on investigator assessment (after that used for PFS) or death, whichever comes first.
Results for this outcome have not been posted.
TTSP is defined as the time from randomization to documentation in the electronic case report form (eCRF) of any of the following (whichever occurs earlier): onset of new symptoms or symptom worsening that is considered by the investigator to be related to lung cancer and requires either a change in anticancer treatment and/or clinical intervention to manage symptoms.
Results for this outcome have not been posted.
Intracranial PFS is defined as the time from randomization until the date of objective intracranial disease progression or death, whichever comes first, based on BICR using RECIST v1.1.
Results for this outcome have not been posted.
Incidence and severity of treatment emergent adverse events (TEAEs) will be reported. Any adverse event occurring at or after the initial administration of study treatment through the day of last dose plus 30 days, or until the start of subsequent anticancer therapy (if earlier), is considered to be treatment emergent.
Results for this outcome have not been posted.
Number of participants with clinical laboratory abnormalities (serum chemistry, hematology, blood coagulation, and urine samples) will be reported.
Results for this outcome have not been posted.
Number of participants with vital signs abnormalities (temperature, heart rate, respiratory rate, oxygen saturation, blood pressure) will be reported.
Results for this outcome have not been posted.
Number of participants with physical examination abnormalities will be reported.
Results for this outcome have not been posted.
Serum samples will be analyzed to determine concentrations of Amivantamab.
Results for this outcome have not been posted.
Plasma samples will be analyzed to determine concentrations of Lazertinib.
Results for this outcome have not been posted.
Number of participants with antibodies to amivantamab will be reported.
Results for this outcome have not been posted.
The NSCLC-SAQ contains 7 items that assess cough, pain, dyspnea, fatigue, and poor appetite over a 7-day recall period. Each multi-item scale and individual item will be summarized using count and percent by visit.
Results for this outcome have not been posted.
EORTC-QLQ-C30 is a core 30-item questionnaire for evaluating the health-related quality of life (HRQoL) of participants participating in cancer clinical studies.
Results for this outcome have not been posted.
Collected over From baseline (Day 1 of Cycle 1) up to 32.8 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Experimental: Arm A (Open-label): Amivantamab + Lazertinib | 96/421 (22.8%) | 205/421 (48.7%) | 419/421 (99.5%) |
| Active Comparator: Arm B (Double-blind): Osimertinib+Placebo Matching Lazertinib | 116/428 (27.1%) | 143/428 (33.4%) | 409/428 (95.6%) |
| Experimental: Arm C (Double-blind): Lazertinib+Placebo Matching Osimertinib | 56/213 (26.3%) | 75/213 (35.2%) | 210/213 (98.6%) |
| Event | Experimental: Arm A (Open-label): Amivantamab + Lazertinib | Active Comparator: Arm B (Double-blind): Osimertinib+Placebo Matching Lazertinib | Experimental: Arm C (Double-blind): Lazertinib+Placebo Matching Osimertinib |
|---|---|---|---|
| Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders | 26/421 | 10/428 | 8/213 |
| PneumoniaInfections and infestations | 17/421 | 21/428 | 7/213 |
| Pleural EffusionRespiratory, thoracic and mediastinal disorders | 9/421 | 17/428 | 3/213 |
| Deep Vein ThrombosisVascular disorders | 12/421 | 2/428 | 1/213 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 4/421 | 11/428 | 2/213 |
| Covid-19Infections and infestations | 10/421 | 10/428 | 3/213 |
| Infusion Related ReactionInjury, poisoning and procedural complications | 9/421 | 0/428 | 0/213 |
| Alanine Aminotransferase IncreasedInvestigations | 8/421 | 6/428 | 4/213 |
| Pericardial EffusionCardiac disorders | 4/421 | 5/428 | 4/213 |
| Aspartate Aminotransferase IncreasedInvestigations | 1/421 | 4/428 | 4/213 |
| Event | Experimental: Arm A (Open-label): Amivantamab + Lazertinib | Active Comparator: Arm B (Double-blind): Osimertinib+Placebo Matching Lazertinib | Experimental: Arm C (Double-blind): Lazertinib+Placebo Matching Osimertinib |
|---|---|---|---|
| ParonychiaInfections and infestations | 288/421 | 121/428 | 61/213 |
| Infusion Related ReactionInjury, poisoning and procedural complications | 261/421 | 0/428 | 0/213 |
| RashSkin and subcutaneous tissue disorders | 260/421 | 131/428 | 95/213 |
| HypoalbuminaemiaMetabolism and nutrition disorders | 204/421 | 26/428 | 17/213 |
| DiarrhoeaGastrointestinal disorders | 123/421 | 189/428 | 68/213 |
| Alanine Aminotransferase IncreasedInvestigations | 152/421 | 55/428 | 47/213 |
| Oedema PeripheralGeneral disorders | 150/421 | 24/428 | 24/213 |
| Dermatitis AcneiformSkin and subcutaneous tissue disorders | 122/421 | 55/428 | 45/213 |
| ConstipationGastrointestinal disorders | 122/421 | 55/428 | 36/213 |
| StomatitisGastrointestinal disorders | 122/421 | 90/428 | 38/213 |
| Age, Continuous(years) | Experimental: Arm A (Open-label): Amivantamab + Lazertinib | Active Comparator: Arm B (Double-blind): Osimertinib+Placebo Matching Lazertinib | Experimental: Arm C (Double-blind): Lazertinib+Placebo Matching Osimertinib | Total |
|---|---|---|---|---|
| Mean | 62.7 ± 10.63 | 61.9 ± 11.52 | 61.3 ± 10.69 | 62.1 ± 11.01 |
| Sex: Female, Male(Participants) | Experimental: Arm A (Open-label): Amivantamab + Lazertinib | Active Comparator: Arm B (Double-blind): Osimertinib+Placebo Matching Lazertinib | Experimental: Arm C (Double-blind): Lazertinib+Placebo Matching Osimertinib | Total |
|---|---|---|---|---|
| Female | 275 | 251 | 136 | 662 |
| Male | 154 | 178 | 80 | 412 |
| Ethnicity (NIH/OMB)(Participants) | Experimental: Arm A (Open-label): Amivantamab + Lazertinib | Active Comparator: Arm B (Double-blind): Osimertinib+Placebo Matching Lazertinib | Experimental: Arm C (Double-blind): Lazertinib+Placebo Matching Osimertinib | Total |
|---|---|---|---|---|
| Hispanic or Latino | 56 | 45 | 24 | 125 |
| Not Hispanic or Latino | 371 | 382 | 190 | 943 |
| Unknown or Not Reported | 2 | 2 | 2 | 6 |
| Race (NIH/OMB)(Participants) | Experimental: Arm A (Open-label): Amivantamab + Lazertinib | Active Comparator: Arm B (Double-blind): Osimertinib+Placebo Matching Lazertinib | Experimental: Arm C (Double-blind): Lazertinib+Placebo Matching Osimertinib | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 7 | 7 | 4 | 18 |
| Asian | 250 | 251 | 128 | 629 |
| Native Hawaiian or Other Pacific Islander | 1 | 1 | 0 | 2 |
| Black or African American | 4 | 3 | 4 | 11 |
| White | 164 | 165 | 79 | 408 |
| More than one race | 1 | 1 | 0 | 2 |
| Unknown or Not Reported | 2 | 1 | 1 | 4 |
| Region of Enrollment(Participants) | Experimental: Arm A (Open-label): Amivantamab + Lazertinib | Active Comparator: Arm B (Double-blind): Osimertinib+Placebo Matching Lazertinib | Experimental: Arm C (Double-blind): Lazertinib+Placebo Matching Osimertinib | Total |
|---|---|---|---|---|
| ARGENTINA | 8 | 11 | 6 | 25 |
| AUSTRALIA | 5 | 7 | 1 | 13 |
| BELGIUM | 2 | 4 | 1 | 7 |
| BRAZIL | 38 | 22 | 9 | 69 |
| CANADA | 0 | 0 | 2 | 2 |
| CHINA | 81 | 79 | 43 | 203 |
| FRANCE | 12 | 11 | 6 | 29 |
| GERMANY | 2 | 5 | 2 | 9 |
| HUNGARY | 2 | 0 | 1 | 3 |
| INDIA | 6 | 16 | 3 | 25 |
| ISRAEL | 3 | 3 | 2 | 8 |
| ITALY | 11 | 8 | 5 | 24 |
| JAPAN | 29 | 32 | 17 | 78 |
| MALAYSIA | 27 | 23 | 10 | 60 |
| MEXICO | 12 | 14 | 5 | 31 |
| NETHERLANDS | 1 | 2 | 0 | 3 |
| POLAND | 7 | 6 | 0 | 13 |
| PORTUGAL | 4 | 2 | 2 | 8 |
| RUSSIAN FEDERATION | 17 | 15 | 8 | 40 |
| SOUTH KOREA | 63 | 68 | 33 | 164 |
| SPAIN | 26 | 33 | 15 | 74 |
| TAIWAN | 24 | 15 | 13 | 52 |
| THAILAND | 15 | 9 | 5 | 29 |
| TURKEY | 15 | 21 | 4 | 40 |
| UKRAINE | 10 | 11 | 10 | 31 |
| UNITED KINGDOM | 2 | 7 | 2 | 11 |
| UNITED STATES | 7 | 5 | 11 | 23 |
Showing the first 100 of 269 sites across 28 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — The data sharing policy of Johnson \& Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Data sharing details ↗ · innovativemedicine.jnj.com
Ran from Sep 2020 to primary completion in Aug 2023, 34 months.
Results were first posted in Oct 2024, 1 year 1 month after primary completion. A results delay was requested in Aug 2024.
Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's 34 months is below that.
Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Amivantamab · Lazertinib
Carcinoma, Non-Small-Cell Lung →
Janssen Research & Development, LLC →